1月5日 - ** 药物开发商AltimmuneALT.O的股价盘前上涨12.8%至3.96美元
** ALT称，美国FDA已授予其治疗一种肝病的实验性药物 "突破性疗法 "标签
** 这种名为培伐度肽的药物正在代谢功能障碍相关性脂肪性肝炎（MASH）患者中进行试验。
** 突破性疗法标签旨在加快对治疗严重疾病或未满足医疗需求的药物的开发和审查。
** 公司表示计划启动一项晚期试验，对52周治疗期内的多种培伐度肽剂量进行评估
** 在过去12个月中，该公司股价下跌了2.8%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.